Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Already had 1.4 Million in the bank

<< Previous

Bullboard Posts

Next >>

Comment by threefiftynineon Jun 25, 2020 6:21pm

47 Views

Post# 31192734

RE:Already had 1.4 Million in the bank

ON or around june 25th 2021----should be enough time to get the funding eh? Unfortunately the oxford boys in England will have the vaccine covered and the blue jays will be playing in front of 50k again----and the .13 cent warrants will be useless

<< Previous

Bullboard Posts

Next >>

Fortuna reports record earnings for Q3 2024